21,148 Shares in CareDx, Inc. (NASDAQ:CDNA) Purchased by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC purchased a new position in shares of CareDx, Inc. (NASDAQ:CDNA - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 21,148 shares of the company's stock, valued at approximately $375,000.

Other large investors have also recently added to or reduced their stakes in the company. Swiss National Bank raised its holdings in CareDx by 1.9% during the fourth quarter. Swiss National Bank now owns 98,600 shares of the company's stock worth $2,111,000 after purchasing an additional 1,800 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in CareDx during the fourth quarter worth about $208,000. Nuveen Asset Management LLC raised its holdings in CareDx by 15.5% during the fourth quarter. Nuveen Asset Management LLC now owns 448,113 shares of the company's stock worth $9,594,000 after purchasing an additional 60,050 shares in the last quarter. Principal Financial Group Inc. raised its holdings in CareDx by 6.5% during the fourth quarter. Principal Financial Group Inc. now owns 18,984 shares of the company's stock worth $406,000 after purchasing an additional 1,151 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in CareDx during the fourth quarter worth about $3,694,000.

Insider Buying and Selling at CareDx

In other news, Director William A. Hagstrom sold 19,391 shares of the stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $19.90, for a total value of $385,880.90. Following the sale, the director directly owned 53,979 shares in the company, valued at $1,074,182.10. This represents a 26.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christine Cournoyer sold 29,136 shares of the stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $15.96, for a total transaction of $465,010.56. Following the completion of the sale, the director owned 37,045 shares in the company, valued at $591,238.20. This represents a 44.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 129,343 shares of company stock valued at $2,238,811 over the last three months. Company insiders own 4.40% of the company's stock.

Analyst Ratings Changes

CDNA has been the topic of several recent analyst reports. Stephens restated an "overweight" rating and set a $40.00 target price on shares of CareDx in a research report on Monday, May 5th. HC Wainwright restated a "neutral" rating and set a $25.00 target price on shares of CareDx in a research report on Monday, May 5th. The Goldman Sachs Group lowered their target price on shares of CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a research report on Thursday, April 17th. Finally, Wall Street Zen lowered shares of CareDx from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $30.33.

CareDx Trading Down 1.5%

Shares of CDNA opened at $19.20 on Friday. The firm's 50-day moving average is $17.78 and its two-hundred day moving average is $19.74. CareDx, Inc. has a twelve month low of $14.09 and a twelve month high of $34.84. The firm has a market capitalization of $1.07 billion, a P/E ratio of 16.69 and a beta of 2.19.

CareDx (NASDAQ:CDNA - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.06 by $0.03. The business had revenue of $84.69 million for the quarter, compared to analyst estimates of $84.56 million. CareDx had a net margin of 19.79% and a return on equity of 21.16%. The company's quarterly revenue was up 17.6% on a year-over-year basis. During the same period in the prior year, the business earned ($0.03) earnings per share. Analysts predict that CareDx, Inc. will post -0.9 EPS for the current year.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.

Want to see what other hedge funds are holding CDNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CareDx, Inc. (NASDAQ:CDNA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.